Telix Pharmaceuticals LTD (TLX) 13F Positioning & Ownership Changes (Q2 2026)

TLX ranks #5624 out of 37501 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

62 institutions disclose a position in TLX, but none treat it as a major bet — even Portland Investment Counsel Inc., its most concentrated holder, allocates just 0.9% of its own portfolio to it.

Fidelity has added to its TLX position for two straight quarters, increasing it by $5.5M to reach $6.5M today.

Vident Advisory, LLC has trimmed its TLX position for two straight quarters, cutting it by $66.3K while still holding $137.8K.

TLX is down 0.7% today, but institutions show net buying of $5.7M this quarter — a divergence between today's price move and the underlying institutional flow.

TLX reported a net loss of $7.1M in its latest fiscal year.

• Not yet profitable — net loss of $7.1M in the latest fiscal year
• Revenue grew 55.6% year over year
• Net income declined year over year, from $33.7M to -$7.1M
• Operating cash flow was negative, using $17.3M in cash
• Current ratio of 1.43x — below the conventional 1.5x liquidity buffer
• Liabilities run 1.80x equity — within a conventional range